AstraZeneca completes acquisition of biopharmaceutical firm Alexion
AstraZeneca has completed the acquisition of biopharmaceutical company Alexion Pharmaceuticals in a deal valued at $39bn. The latest move comes after the receipt of clearance from the UK
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.